Partner Paul Jin provides an overview of merger control activity in the last 12 months, share new developments in jurisdictional assessment and discuss key industry sectors and policy developments in the antitrust merger enforcement sector.
Read the full article.
Related Content
- AlertApril 25, 2024
FTC Issues Final Rule Prohibiting Most Post-Employment Non-Compete Agreements
- InsightApril 24, 2024
European Commission’s First-Ever Abuse of Dominance Probe for Shelving of a Novel Pipeline Therapy
- InsightApril 24, 2024
Healthcare M&A and Financing Trends and Predictions for 2024
- AlertApril 15, 2024
Delaware Supreme Court Holds That Boards Must Satisfy the MFW Framework in Controller Transactions to Obtain Business Judgment Deference
- NewslettersApril 4, 2024
SEC Adopts Reforms Relating to Investment Advisers Operating Exclusively Through the Internet
- Alert28 March 2024
At the Intersection of ‘S’ and ‘G’ of ESG: London Leading the Way on Board Diversity — An Update on Latest FTSE Women Leaders Review and Parker Review Reports
- NewslettersMarch 28, 2024
Agencies Extend Applicability Date of Certain Provisions of their CRA Final Rule
- NewslettersMarch 21, 2024
FinCEN Publishes an Administrative Ruling Regarding Customer Identification Program and Customer Due Diligence Requirements for Designated Beneficiaries of Individual Retirement Accounts
- Speaking EngagementsMay 14, 2024
What Tech Companies Need to Know: State of Tech M&A Panel
- Press ReleaseApril 11, 2024
Digital Markets Guide: US Skepticism of Tech Transactions Sparks a Step-Up in Merger Enforcement (GCR)
- Press ReleaseApril 10, 2024
Alpine Immune Sciences To Be Acquired by Vertex Pharmaceuticals For $4.9 Billion
- Press ReleaseApril 10, 2024
Auradine Raises $80 Million in Series B Financing and Achieves $80 Million in Bookings
- In the PressApril 9, 2024
Deal Watch: M&A (Law.com)
- In the PressApril 4, 2024
US Law Firms Ride Rising M&A Wave in Q1 (Reuters)
- In the PressApril 4, 2024
Q1 PE League Tables: Making it Private (The Deal)
- Press ReleaseApril 3, 2024
AlmataBio Acquired by Avalo Therapeutics For $22.5 Million